CDK12-IN-2 |
Catalog No.GC63499 |
CDK12-IN-2 est un inhibiteur de CDK12 puissant, sélectif et nanomolaire (IC50 = 52 nM) avec de bonnes propriétés physicochimiques. CDK12-IN-2 est également un puissant inhibiteur de CDK13 car CDK13 est l'homologue le plus proche de CDK12. CDK12-IN-2 montre une excellente sélectivité de kinase pour CDK12 sur CDK2, 9, 8 et 7. CDK12-IN-2 inhibe la phosphorylation de Ser2 dans le domaine C-terminal de l'ARN polymérase II. CDK12-IN-2 peut être utilisé comme une excellente sonde chimique pour les études fonctionnelles de CDK12.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2244987-03-7
Sample solution is provided at 25 µL, 10mM.
CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12[1].
CDK12-IN-2 inhibits the phosphorylation of the CTD Ser2 in SK-BR-3 cells at low submicromolar concentrations, it inhibits C-terminal domain ser2 phosphorylation with an IC50 of 185 nM. And CDK12-IN-2 exhibits a growth inhibition with an IC50 of 0.8 μM in SK-BR-3 cells[1].CDK12-IN-2 exhibits time dependency for CDK12 inhibition, the IC50 value for CDK12-IN-2 are 0.0078 μM, 0.042 μM, 0.057 μM,and 0.059 μM, for 0h, 1h, 2h and 5h respectively[1].
[1]. Masahiro Ito, et al. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. J Med Chem. 2018 Sep 13;61(17):7710-7728.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *